Better Food Ventures
Menlo Park, United StatesInvestor highlights
- Industry focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| STRM.BIO , a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy | Jul 1, 2026 | Biotechnology, Gene Editing, Immune Cell Engineering, RNA Therapeutics | Early stage | 8000000 USD | MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, a Cambridge |
| TRexBio , a San Francisco, CA-based clinical-stage biotechnology company | Jan 27, 2026 | Biotechnology, Computational Biology, Immunoregulatory Medicines | - | 50000000 USD | CA-based clinical-stage biotechnology company, a San Francisco |
| Ensoma | Sep 23, 2025 | Autoimmune Disease, Cancer, DNA Editing, Genetic Disease, Genetic Medicines, Genome Engineering, Genomic Medicines, Hematopoietic Stem Cell Engineering, Immuno-oncology, Inherited Conditions, In Vivo Delivery, Sickle Cell Disease | - | 53000000 USD | Boston, Massachusetts |
| Avenzo Therapeutics | Sep 22, 2025 | Antibody-Drug Conjugates (ADCs), Biotechnology, CDK2 Inhibitor, Oncology, Oncology Pipeline, Pharmaceuticals, Small Molecules | - | 60000000 USD | San Diego, California |
| TRexBio | Nov 14, 2024 | Biotechnology, Computational Biology, Immunobiology, Therapeutics | Growth stage | 84000000 USD | San Francisco, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.